View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Sponsored by

When Clinical Trials Meet the Real World

The biopharma industry faces a troubling problem: Trial design is foundering on multiple fronts. About 64 percent of phase three trials fail, and about two thirds of these failures occur due to flawed design, inappropriate endpoints or under-enrollment. Even when trials don’t fail, they incur on average 1.5 institutional review board (IRB) amendments per trial, costing roughly $500,000 each and potentially delaying trials for months. Many biopharma companies do not fully embed value in their clinical development programs, and struggle with achieving uptake or demonstrating the value of the new therapies they’ve worked so hard to develop. That’s because real world patients often look very different from trial patients, or because the clinical guidelines don’t match up with the new therapies. When drugs work in the lab, but not out in the real world, doctors don’t want to prescribe them and patients don’t want to take them.

Download to find out more.

Websites in our network
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU